LY 530217
Latest Information Update: 23 Mar 2009
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Neuroprotectants; Small molecules; Sulfonamides
- Mechanism of Action Metabotropic glutamate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 23 Mar 2009 Discontinued - Preclinical for Neurological disorders (Prevention) in USA (unspecified route)
- 23 Apr 2002 Preclinical trials in Neurological disorders (Prevention) in USA (unspecified route)